BioXcel Therapeutics (BTAI) Misses Q3 EPS by 45c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q3 EPS of ($1.72), $0.45 worse than the analyst estimate of ($1.27). Revenue for the quarter came in at $341 thousand versus the consensus estimate of $625.81 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Bernstein SocGen Group Upgrades Engie SA (ENGI:FP) (ENGIY) to Outperform
• Here Group posts FY2026 results with $88M revenue, goodwill write-down